We continue to hear from long-term users of this drug who suffered atypical femur fractures. We look forward to additional progress in this litigation in the coming year.
New York, New York (PRWEB) June 01, 2013
Hundreds of Fosamax lawsuit claims continue to move forward in a consolidated litigation now underway in New Jersey’s Atlantic County Superior Court, Bernstein Liebhard LLP reports. According to a posting on the Court’s website, the next Case Management Conference in the New Jersey Fosamax side effect litigation will be held on Tuesday, June 11th. (In re: Fosamax Litigation, No. 282, N.J. Super. Ct)
“We continue to hear from long-term users of this drug who suffered atypical femur fractures. We look forward to additional progress in this litigation in the coming year,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is actively filing Fosamax lawsuits on behalf of patients who allegedly suffered femur fractures due to their use of this drug.
Court records indicate that more than 2600 Fosamax side effects claims have been filed in the New Jersey litigation. The nation’s first Fosamax trial involving femur fracture allegations concluded in that litigation in April, with a finding for Merck & Co. During the trial, the Plaintiff claimed that Merck began hearing from its own consultants five years before its 1995 approval that Fosamax could lead to spontaneous fractures in some users. She also alleged that Fosamax became widely over-prescribed after doctors began relying on bone-mass density testing to diagnose osteoporosis, rather than the use of clinical criteria such as prior bone fractures. (Glynn v. Merck Sharp & Dohme Corp., 3:11- cv-05304, U.S. District Court, District of New Jersey)
More than 800 Fosamax femur fracture claims are also pending in a federal multidistrict litigation underway in U.S. District Court, District of New Jersey. (In re: Fosamax (Alendronate Sodium) Products Liability Litigation (No. II) - MDL No. 224) Earlier this year, that proceeding’s first trial was declared a mistrial after the Plaintiff became ill. That trial has yet to be rescheduled. (Su v. Merck Sharp & Dohme Corp., case number ATL-L-0789-11)
Fosamax femur fracture lawsuits began to mount in courts around the country following an October 2010 advisory from the U.S. Food & Drug Administration (FDA) regarding an association between drugs like Fosamax and atypical femur fractures* Since then, a growing body of research has raised questions about the long-term use of Fosamax, including an FDA-commissioned study published in May 2012 that concluded there was little benefit in taking such drugs for longer than five years due to their association with femur fractures and other side effects.**
Alleged victims of Fosamax side effects, including femur fractures, could be entitled to compensation for medical bills, lost wages, pain and suffering, and other damages. A wealth of information regarding Fosamax lawsuits is available by visiting Bernstein Liebhard LLP’s website. To learn more, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com